Inflammation score, defined by the abundance of CD45+ immune cell clusters and E-selectin+ vessels, was disproportionally high around residual human breast tumors (score of 3 in 42% of residual vs. 6% of no residual tumor cases; Figure 1a). The gene discussed is PTPRC; the disease is breast neoplasm.